PI3K/Akt/mTOR Signaling - Selective - GSK-3 - MELK - mTOR
The PI3K/Akt/mTOR signaling pathway is a key regulator in growth, survival, cell cycle proliferation, protein synthesis and glucose metabolism. Growth factors, hormones, and cytokines can activate this pathway by binding their cognate receptor tyrosine kinase (RTK), cytokine receptor, or GPCR, resulting in the activation of lipid kinase PI3K which produces PIP3 at the plasma membrane.
The binding of PIP3 translocates Akt to cell membranes, enables Akt activation through phosphorylation at Thr308 mediated by phosphoinositide dependent kinase 1 (PDK1). In addition, Akt is phosphorylated at Ser473 by the mTOR-rictor complex, mTORC2. PTEN is a negative regulator of Akt signaling that reverses the function of PI3K by removing 3’-phosphate groups. Akt activity is also negatively regulated by the phosphatases PP2A and PHLPP. Akt propagates its signal to affect DNA transcription, cell cycle and apoptosis. Akt can activate mTOR directly by phosphorylation or indirectly, by phosphorylation and inactivation of mTOR inhibitor TSC2 and PRAS40. Together these mechanisms stimulate cell growth and G1 cell cycle progression through signaling via p70 S6 Kinase and inhibition of 4E-BP1. Defects in PI3K/AKT/mTOR signaling are implicated in cancer, diabetes and cardiovascular disease etc.
- B6099 LY3023414Target: Akt|PI3K|mTOR|DNA-PKSummary: I类PI3K,mTOR和DNA-PK抑制剂
- B5853 MHY14852 CitationTarget: mTORSummary: mTOR激活剂,自噬抑制剂
- B3672 Indirubin中文名: 靛玉红Target: Cyclin-Dependent Kinases|GSK-3Summary: 细胞周期蛋白依赖性激酶和GSK-3β抑制剂
- B1641 WAY-600Target: mTORSummary: MTOR抑制剂
- B1639 Ridaforolimus (Deforolimus, MK-8669)中文名: 地磷莫司,利罗莫司Target: mTORSummary: mTOR抑制剂
- B1321 OTSSP167Target: MELKSummary: MELK抑制剂
- B1536 AZD10801 CitationTarget: GSK-3Summary: GSK3β抑制剂
- B1640 Torin 21 CitationTarget: mTOR|DNA-PK|ATM/ATRSummary: MTOR抑制剂
- B2172 PP121Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|HckSummary: 酪氨酸激酶和磷酸肌醇激酶双重抑制剂
- B1642 WYE-125132 (WYE-132)Target: mTORSummary: mTOR抑制剂